Bristol Myers' lung drug admilparant meets Phase 3 goal at low dose, high dose falls short

Bristol Myers Squibb reported that its experimental idiopathic pulmonary fibrosis therapy admilparant achieved its primary endpoint in a Phase 3 trial, showing a statistically significant slowing of breathing decline compared with placebo over a year.

The benefit was observed only in participants receiving the 60 mg dose. The higher 120 mg dose also showed a trend toward slower disease progression, but the result did not reach statistical significance, leading analysts to describe the outcome as confounding.

The company said the drug maintained a well‑tolerated safety profile, with discontinuation rates similar between treatment arms, despite earlier trial revisions that raised liver‑related safety concerns.

Analysts noted the mixed dose response raises questions about the drug’s commercial prospects and may require additional data to clarify the optimal dosing strategy.